Phase 2 trial of monoamine oxidase inhibitor phenelzine in biochemical recurrent prostate cancer

• Published in: Prostate cancer and prostatic diseases Vol. 24; no. 1; pp. 61 - 68
• Main Authors: Gross, Mitchell E., Agus, David B., Dorff, Tanya B., Pinski, Jacek K., Quinn, David I., Castellanos, Olga, Gilmore, Patrick, Shih, Jean C.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.03.2021; Nature Publishing Group
• Subjects: 692/308/575; 692/699/67/589/466; Adenocarcinoma - blood; Adenocarcinoma - drug therapy; Adenocarcinoma - pathology; Aged; Amine oxidase (flavin-containing); Antianxiety agents; Anxiety; Biochemistry; Biomarkers, Tumor - blood; Biomedical and Life Sciences; Biomedicine; Cancer Research; Cancer surgery; Cancer therapies; Clinical trials; Depression, Mental; Disease-Free Survival; Diseases; Dose-Response Relationship, Drug; Drug Administration Schedule; Edema; Follow-Up Studies; Humans; Hypertension; Inhibitors; Male; Medical colleges; Metastases; Metastasis; Middle Aged; Monoamine Oxidase Inhibitors - administration & dosage; Mood; Neoplasm Recurrence, Local - blood; Neoplasm Recurrence, Local - drug therapy; Neoplasm Recurrence, Local - pathology; Neoplasm Staging; Oxidase; Oxidases; Patients; Phenelzine - administration & dosage; Post-radiation; Prostate cancer; Prostate-Specific Antigen - blood; Prostatectomy; Prostatic Neoplasms - blood; Prostatic Neoplasms - drug therapy; Prostatic Neoplasms - pathology; Questionnaires; Radiation therapy; Radiotherapy; Relapse; Syncope; Treatment Outcome; Urological surgery

Purpose Monoamine oxidase A (MAOA) influences prostate cancer growth and metastasis in pre-clinical models. We examined effects of phenelzine (a monoamine oxidase inhibitor) in patients with biochemical recurrent castrate-sensitive prostate cancer. Materials and methods An open-label single arm clin...